DENVER — In this video, April W. Armstrong, MD, MPH, discusses data presented at the American Academy of Dermatology Annual Meeting, for amlitelimab, IL-4 receptor antagonists, zumilokibart and STAT6 degrader molecules.
The results from a phase 3 study for amlitelimab (Sanofi) showed steady improvement in patient EASI and IGA scores at 24 weeks. Long-term data regarding use, dosing frequency and efficacy beyond 24 weeks is forthcoming.  In addition, phase three results for two new biologics, both IL-4 receptor antagonists, showed enhanced efficacy and binding to the target for the

NEW ORLEANS — For orthopedic surgery candidates with obesity, preoperative weight loss may not correlate with perioperative risk reduction and may be an oversimplification of a nuanced dynamic, according to a presenter.
“It is wrong to assume that forcing a patient to lose weight will end up reducing their perioperative risk,” Nicholas J. Giori, MD, PhD, professor of orthopedic surgery at Stanford University and chief of orthopedic surgery at the VA Palo Alto Health Care System, told Healio. “There is likely a more complex relationship between weight and complications — possibly affected by

PHILADELPHIA — The risk for peanut allergy was heightened among younger siblings living in a household with people consuming peanut, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“These findings support the concept that peanut allergy can develop with exposure to peanut through the skin, and that this risk can be overcome by introducing peanut into the diet at an early age,” Michelle Huffaker, MD, FAAAAI, allergist and immunologist with Stanford Health Care, said in a press release.
Using data from the Learning Early About Peanut (LEAP)